[18F]fluoride PET indicates reduced bone formation in severe glucocorticoid-induced osteoporosis

G Berding; T D Kirchhoff; W Burchert; J von der Hoff; H Zeidler; H Hundeshagen; W H Knapp

[18F]fluoride PET indicates reduced bone formation in severe glucocorticoid-induced osteoporosis

Nuklearmedizin. 1998 Mar;37(2):76-9.

Authors

G Berding¹, T D Kirchhoff, W Burchert, J von der Hoff, H Zeidler, H Hundeshagen, W H Knapp

Affiliation

¹ Klinik für Nuklearmedizin, Medizinischen Hochschule Hannover, Germany. berding.georg@mh-hannover.de

PMID: 9547755

Abstract

A 61-year-old female patient presenting with mixed connective tissue disease (Sharp syndrome), underwent a long-term high dose glucocorticoid treatment because of multiple organ manifestations. Under steroid therapy she developed severe osteoporosis resulting in multiple fractures. A dynamic [18F]fluoride PET study in this patient revealed reduced fluoride influx in non-fractured vertebrae. This finding corresponds to pathogenetic concepts which propose an inhibition of bone formation as major cause of glucocorticoid-induced osteoporosis. In the light of the presented case it seems to be promising to evaluate the diagnostic benefit of [18F]fluoride PET in osteoporosis.

Publication types

Case Reports

MeSH terms

Esophagus / diagnostic imaging
Female
Fluorides
Fluorine Radioisotopes*
Fractures, Bone / diagnostic imaging
Fractures, Bone / etiology
Glucocorticoids / adverse effects*
Humans
Magnetic Resonance Imaging
Methylprednisolone / adverse effects*
Middle Aged
Mixed Connective Tissue Disease / diagnosis
Mixed Connective Tissue Disease / drug therapy*
Mixed Connective Tissue Disease / physiopathology
Osteoporosis / chemically induced
Osteoporosis / diagnostic imaging*
Radiopharmaceuticals
Respiratory Function Tests
Technetium Tc 99m Medronate
Tomography, Emission-Computed
Tomography, X-Ray Computed

Substances

Fluorine Radioisotopes
Glucocorticoids
Radiopharmaceuticals
Fluorides
Methylprednisolone
Technetium Tc 99m Medronate